3i Group plc

The Consumer sector is a big space, with a risk of cyclical market performance. Being in the right part is what matters. That’s why 3i targets segments that balance both growth and resilience, with attractive opportunities including wellness, discount retail, pet food and leisure. Learn more about our consumer growth strategy in Pierre-Axel Botuha's interview with PEI.

3i has a clear plan to grow and create value within our consumer portfolio. Our key value-creation pillars include attracting talent, leveraging M&A, international growth, expanding sales channels, and developing brands and products. Learn more about the value-creation levers we use to help consumer brands scalein Pierre-Axel Botuha's interview with PEI.

Investing in consumer brands does not need to trap you in the business cycle. At 3i, our consumer investment strategy is focused on finding brands that combine strong growth drivers with resilience. The scale of the Consumer sector means there are always pockets of growth. Learn more about our differentiated approach in Pierre-Axel Botuha's interview with PEI.

Cyclicality works both ways. While there’s downside risk, there are many opportunities on the upside. 3i manages this through portfolio construction. We balance premium branded products with value-orientated companies, all while targeting businesses with winning propositions regardless of price point. Learn more about our differentiated approach in Pierre-Axel Botuha's interview with PEI.

Meeting the scale requirements of the largest global medtech OEMs requires design centers of excellence paired with highly-efficient manufacturing. For the final in our ‘Scaling with Customers’ series, focused on high-growth life sciences and medtech companies, we’re looking at the need for a partner that can reduce handoffs, improve execution, and support scale across a broad range of device applications that can serve the global market efficiently. Our portfolio company QMD - DEGANIA I BIOMETRIX I ARTHESYS has expanded its manufacturing and assembly presence in India to: • Include injection molding, • Expand multi-lumen silicone and thermoplastic extrusion, • And develop assembly of complex devices. In addition to these initiatives, 3i has supported QMD to develop devices like PTCA and PTA catheters and in-house sterilization. With 3i’s help, QMD now has a team of almost 1,000 FTEs producing millions of catheters annually. Read the full case study via the link in the comments.

For pharmaceutical and biotech companies, the transition from research into clinical then to commercial scale can be a critical challenge. For the next in our ‘Scaling with Customers’ series, focused on high-growth life sciences and medtech companies, we’re looking at the need for capabilities and capacity that is available, technically fit-for-purpose, validated, and supported by robust quality systems. As injectable biologics and complex drug products continue to grow, our portfolio company ten23 health has invested ahead of that need, enabling it to partner with customers to: 1) Enhance development, 2) Expand clinical supply, 3) And strengthen commercial readiness. 3i has supported ten23 to roll out two new manufacturing lines that are adding meaningful capacity for sterile fill-finish across vials, syringes, and cartridges, with high-precision filling and stopper setting and high-end process controls. Read the full case study for more information.